Navigation Links
Optimer Pharmaceuticals' Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Date:8/19/2010

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the European Medicines Agency (EMA) has accepted for review Optimer's Marketing Authorization Application (MAA) for fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI in the European Union (EU).  Optimer announced the submission of its MAA for fidaxomicin to the EMA on August 2, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"An independent survey recently conducted by Decision Resources indicates that CDI is on the rise and that nearly 70% of surveyed infectious disease specialists and internists would use fidaxomicin in first- and second-line treatment of CDI, if approved," said Pedro Lichtinger, President and CEO of Optimer. "We believe the potential demand for a narrow spectrum antibiotic with lower recurrence rates for the treatment of CDI is significant. The acceptance for review of the fidaxomicin marketing application by the EMA is an important step in bringing this much needed therapy to Europe, where treatment options are limited.  With the validation of this MAA, we believe we have significantly improved the risk profile of our European program that when combined with our growing excitement and understanding of CDI incidence, access and prescribing intentions across the region, present an enhanced value proposition for fidaxomicin."  

Given these developments, the Company is increasing its focus on its European partnering process for fidaxomicin. J.P. Morgan has been engaged to advise and assist Optime
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 TWi Biotechnology, Inc., today ... for AC-201, TWi Biotechnology,s lead drug candidate, from ... China for patent application numbered 201180018154.8.  ... salts, active metabolite for treatment of type II ... treatment using AC-201 for type II diabetes, and ...
(Date:12/19/2014)... 19, 2014 You,re visiting the dentist for ... when he or she says you need a root ... you may have several questions and feel apprehensive about ... know it,s nothing to worry about. The Pennsylvania Dental ... alleviate any anxiety the public may have surrounding this ...
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
Breaking Medicine Technology:TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2Building a Best-in-Class Pharma Global Brand Website 2
... Pa., July 28, 2011 Kensey Nash Corporation (Nasdaq: ... earnings results for its fourth quarter and fiscal year ended ... August 18, 2011.   Joe Kaufmann, President and ... on Thursday, August 18, 2011 at 9:00 A.M. Eastern Time. ...
... 2011 Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today that ... to be held August 9-11, 2011 at the InterContinental Boston ... Officer, is scheduled to present an overview of the Company ... To listen to the audio web cast of ...
Cached Medicine Technology:Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference 2Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011 2
(Date:12/22/2014)... New York, NY (PRWEB) December 22, 2014 ... a noticeable toll and can present in the form ... nasolabail folds with the start of the marionette line ... peels, topical treatments and diligent skincare, but as the ... Radiesse, and Restylane are all synthetic fillers that can ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic ... to their ad hoc report writing service to meet ... sign up for an annual subscription and get a ... a deeply discounted hourly rate. , Customers can ... progressively discounted rate. Subscription hours are contracted in 25 ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The holidays are ... of the season. Many may be thinking about how to ... of a few weeks. Health Republic Insurance of New York ... Dietitian, Andrea Chernus, to provide some smart ideas to enjoy ... healthy. , 1)    Avoid arriving at a holiday gathering over-hungry , ...
(Date:12/22/2014)... new vaccine created to fight an illness similar to ... and even humans from similar brain infections, researchers report. ... becoming infected by the incurable brain disorder known as ... Dec. 21 online edition of the journal Vaccine ... particles known as prions that go rogue. Prion ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Super Saturday, ... Friday this year as the busiest day in the ... retailers, The Grass Station had a steady pre-Christmas stream ... gifts, this past Saturday. , “I definitely intend to ... Robert, a Denver resident who was enjoying The Grass ...
Breaking Medicine News(10 mins):Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2
... , JACKSONVILLE, Fla., Aug. 18 ... Blue Cross and Blue Shield of Florida (BCBSF), announced today that ... receive funding from Partners Investing in Nursing,s Future , a ... nurses across the country. To date, this is the first Florida ...
... , New data show nanotechnology-related ... , WASHINGTON, Aug. 18 Every state can ... Data released today by the Project on Emerging Nanotechnologies ... organizations across all 50 U.S. states and in the District of ...
... , EDISON, N.J., Aug. 18 Digitek Medication ... various heart conditions, such as abnormal heart rhythms (atrial fibrillation & atrial ... potent that even a slight increase in dosage can be toxic or ... has suffered digitalis toxicity or symptoms associated with digitalis toxicity as a ...
... disordered breathing to deadly cardiovascular complications , TUESDAY, ... sleep apnea -- loud snoring, interrupted breathing and sleep ... and premature death among middle-aged and elderly men, according ... moderate sleep apnea face an increased death risk, as ...
... 10 physician groups in national experiment, U-M Faculty Group Practice demonstrates ... , ANN ARBOR, Mich., Aug. 18 Medicare patients ... getting better treatment than ever at the University of Michigan Health ... report. , , These results come from ...
... , , , , ... Mobility Solutions business of Motor o la, ... Motorola AirDefense Wireless Vulnerability Assessment solution , a ... networks. This innovative solution provides a completely new method to secure ...
Cached Medicine News:Health News:The Blue Foundation for a Healthy Florida Receives Grant to Address National/Regional Nursing Shortages 2Health News:The Blue Foundation for a Healthy Florida Receives Grant to Address National/Regional Nursing Shortages 3Health News:The Blue Foundation for a Healthy Florida Receives Grant to Address National/Regional Nursing Shortages 4Health News:The Blue Foundation for a Healthy Florida Receives Grant to Address National/Regional Nursing Shortages 5Health News:Putting Nanotechnology on the Map 2Health News:Putting Nanotechnology on the Map 3Health News:Digitek Medication Recalled Due to Risk of Digitalis Toxicity 2Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 2Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 3Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 4Health News:U-M Improved Preventive and Chronic Care and Saved Medicare $$ 2Health News:U-M Improved Preventive and Chronic Care and Saved Medicare $$ 3Health News:U-M Improved Preventive and Chronic Care and Saved Medicare $$ 4Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 2Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 3Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 4Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 5
... Accutest H. pylori WB test ... the qualitative detection of lgG ... in human whole blood. This ... an aid in the diagnosis ...
... is an FDA approved rapid ... blood test used to aid ... infection. This CLIA waived test, ... antibodies to HIV-1, requires only ...
... QuickVue+ Infectious Mononucleosis test is ... antibodies in serum, plasma or whole ... utilizes an extract of bovine erythrocytes ... specificity than similar extracts prepared from ...
... the first available point-of-care diagnostic test that ... of influenza A and B. The test ... an enzyme that assists viral replication by ... infected cells. The ZstatFlu substrate is labeled ...
Medicine Products: